Dare Bioscience Inc Webinar: KOL Discussion and Data Review of Exploratory Phase 2b RESPOND Study of Sildenafil Cream Transcript
Good afternoon. My name is Emma, and I will be your conference operator today. At this time, I would like to welcome everyone to the Daré Bioscience webinar to discuss data from the exploratory Phase 2b RESPOND study of Sildenafil Cream. (Operator Instructions)
Sabrina Martucci Johnson, Chief Executive Officer of Daré Bioscience, I'll turn the call over to you.
© -
Great. Thank you so much and thank you for those of you who are listening in to the webinar today. If you follow Daré, you know, we are a company focused solely on women's health with a broad asset of portfolios -- and our assets in our portfolio across a variety of indications that we are very, very thrilled today to be hosting this KOL discussion and data review of the Phase 2b RESPOND study results of Sildenafil Cream.
So without further ado, we're very much looking forward to digging in.
Obviously, the presentation today will contain and does contain forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |